RespireRx Pharmaceuticals Inc. Announces that Jeff Margolis, the Company’s CFO is presenting at the Investor Summit Q4
10. November 2022 08:45 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
RespireRx Pharmaceuticals Inc. Announces that Dr. Arnold Lippa Is an Invited Speaker at the 5th Meridian Drug Discovery Summit
07. November 2022 08:45 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
RespireRx Pharmaceuticals Inc. Announces that Sleep Review has discussed the RespireRx Dronabinol Obstructive Sleep Apnea (OSA) Program in its June 13, 2022 Edition
08. August 2022 08:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
RespireRx Pharmaceuticals Inc. Announces that Dr. Arnold Lippa is an Invited Speaker at the 5th International Cannabinoid-Derived Pharmaceuticals Summit
24. Mai 2022 08:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., May 24, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary...
RespireRx Pharmaceuticals Inc. Announces Recent RespireRx Presentation at 2022 GRI Virtual Conference presented by CureGRIN and GRIN Therapeutics.
17. Mai 2022 08:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary...
RespireRx Pharmaceuticals Inc. Announces Patent Filings Claiming Novel Lipid Based Formulations for Insoluble Compounds, Including Cannabinoids Such as Dronabinol
23. März 2022 08:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
RespireRx Pharmaceuticals Inc. Announces Discovery of a New GABAkine Neuromodulator that Protects Against Seizures and Lethality
16. März 2022 08:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., March 16, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
Letter to Stockholders and Other Stakeholders: A Brief Summary of Our Progress During Past Twelve Months and a Peek Looking Forward
07. März 2022 08:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
RespireRx Pharmaceuticals Inc. Announces Publication of a Manuscript Describing Its Newest Neuromodulator for Pharmacoresistant Epilepsy and Chronic Pain
24. Januar 2022 07:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Jan. 24, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...